Sei in: Home > Gruppi > Prodotti della ricerca

Biochemistry and Molecular Biology (BMB)

 REFERENCES 
1. Oliaro-Bosso S., Viola F., Taramino S., Tagliapietra S., Barge A., Cravotto G.  and Balliano G.  Inhibitory Effect of Umbelliferone Aminoalkyl Derivatives on Oxidosqualene Cyclases fromSaccharomyces cerevisiaeTrypanosoma cruziPneumocystis carinii, Homo sapiens and Arabidopsis thaliana: a structure-activity study. Chem. Med. Chem. 2, (2007),226-233.

2.  Balliano G., Dehmlow H., Oliaro-Bosso S., Scaldaferri M.,Taramino S.,Viola F., Caron G., Aebi J., Ackermann J. Oxidosqualene cyclase from Saccharomyces cerevisiaeTrypanosoma cruzi,Pneumocystis carinii and Arabidopsis thaliana expressed in yeast: A model for the development of novel antiparasitic agents. Bioorg. Med. Chem. Lett.19(2009), 718–723.

3. S. Oliaro-Bosso, G. Caron, S. Taramino, G. Ermondi, F. Viola, G. Balliano. Characterization of the channel constriction allowing the access of the substrate to the active site of yeast oxidosqualene cyclase. PLoS ONE (2011), 6(7): e22134. doi:10.1371/journal.pone.0022134.

4. C. Mo, P. Milla, K. Athenstaedt, R. Ott, G. Balliano, G. Daum, and M. Bard. In yeast sterol biosynthesis the 3-keto reductase protein (Erg27p) is required for oxidosqualene cyclase (Erg7p) activity.Biochim. Biophys. Acta 1633 (2003), 68-74.

5. M. Ghiazza, E. Carella, S. Oliaro-Bosso, I. Corazzari, F. Viola, I. Fenoglio. (2013) Predictive tests to evaluate oxidative potential of engineered nanomaterials. Nanosafe 2012: International Conferences on Safe Production and Use of Nanomaterials, Journal of Physics: Conference Series 429, 012024-012032.

6. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144 (2011), 646-74.

7. Serini G, Bussolino F, Maione F, Giraudo E. Class 3 semaphorins: physiological vascular normalizing agents for anti-cancer therapy. J Intern Med. 273 (2013), 138-55.

8. Maione F, Molla F, Meda C, Latini R, Zentilin L, Giacca M, Seano G, Serini G, Bussolino F, Giraudo E. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. J Clin Invest. 119 (2009), 3356-72.

9. Maione F, Capano S, Regano D, Zentilin L, Giacca M, Casanovas O, Bussolino F, Serini G, Giraudo E. Semaphorin 4A exerts a proangiogenic effect by enhancing vascular endothelial growth factor-A expression in macrophages. J Clin Invest. 122 (2012), 1832-48.

NOPhArm (DRUG DESIGN- NO Prodrugs and hybrids)

Most significant recent publications (years 2008-2013)
Riganti, C.; Rolando, B.; Kopecka, J.; Campia, I.; Chegaev, K.; Lazzarato, L.; Federico, A.; Fruttero, R.; Ghigo, D. Mitochondrial-targeting nitrooxy-doxorubicin: a new approach to overcome drug resistance. Mol. Pharmaceutics 201310, 161-174  doi

Bertinaria, M.; Shaikh, M. A. A. G.; Buccellati, C.; Cena, C.; Rolando, B.; Lazzarato, L.; Fruttero, R.; Gasco, A.; Hoxha, M.; Capra, V.; Sala, A. Rovati, G. E. Designing multitarget anti-inflammatoryagents: chemical modulation of the lumiracoxib structure toward dual thromboxane antagonists-COX-2 inhibitors.ChemMedChem 2012, 7, 1647-1660  doi

Bertinaria, M.; Rolando, B.; Giorgis, M.; Montanaro, G.; Marini, E.; Collino, M.; Benetti, E.; Daniele, P. G.; Fruttero, R.; Gasco, A. Carnosine analogues containing NO-donor substructures: synthesis, physico-chemical characterization and preliminary pharmacological profile. Eur.J. Med. Chem. 201254, 103-112  doi

Patruno, A.; Tosco, P.; Borretto, E.; Franceschelli, S.; Amerio, P.; Pesce, M.; Guglielmo, S.; Campiglia, P.; Bernengo, M. G.; Fruttero, R. Thymopentin down-regulates both activity and expression of iNOS in blood cells of Sézary syndrome patients. Nitric Oxide 201227, 143-149  doi

Cena, C.; Tosco, P.; Marini, E.; Lazzarato, L.; Piccinini, M.; Ramondetti, C.; Lupino, E.; Fruttero, R.; Gasco, A. Nitrooxyacyl derivatives of salycilic acid: aspirin-like molecules that covalently inactivate cyclooxygenase-1. ChemMedChem 20116, 523-530.  doi

Bertinaria, M.; Rolando, B.; Giorgis, M.; Montanaro, G.; Guglielmo, S.; Buonsanti, M. F.; Carabelli, V.; Gavello, D.; Daniele, P. G.; Fruttero, R.; Gasco, A. Synthesis, physicochemical characterisation and biological activities of new carnosine derivatives stable in human serum as potential neuroprotective agents. J. Med. Chem. 201154, 611-621  doi

Bertinaria, M.; Guglielmo, S.; Rolando, B.; Giorgis, M.; Aragno, C.; Fruttero, R.; Gasco, A.; Parapini, S.; Taramelli, D.; Martins, Y. C.; Carvalho, L.J. Amodiaquine analogues containing NO-donor substructures: Synthesis and their preliminary evaluation as potential tools in the treatment of cerebral malaria. Eur. J. Med. Chem. 201146, 1757-1767  doi

Lazzarato, L.; Chegaev, K.; Marini, E.; Rolando, B.; Borretto, E.; Guglielmo, S.; Joseph, S.; Di Stilo, A.; Fruttero, R.; Gasco, A. New nitric oxide or hydrogen sulfide releasing aspirins. J. Med. Chem. 201154, 5478-5484  doi

Chegaev, K.; Riganti, C.; Lazzarato, L.; Rolando, B.; Guglielmo, S.; Campia, I.; Fruttero, R.; Bosia, A.; Gasco, A. Nitric oxide donor doxorubicins accumulate into doxorubicin-resistant human colon cancer cells inducing cytotoxicity. ACS Med. Chem. Lett. 20112, 494-497  doi

Fruttero, R.; Crosetti, M.; Chegaev, K.; Guglielmo, S.; Gasco, A.; Berardi, F.; Niso, M.; Perrone, R.; Panaro, M. A.; Colabufo, N. A. Phenylsulfonylfuroxans as modulators of multidrug-resistance-associated protein-1 and P-glycoprotein. J. Med. Chem. 201053, 5467-5475  doi

Lazzarato, L.; Donnola, M.; Rolando, B.; Chegaev, K.; Marini, E.; Cena, C.; Di Stilo, A.; Fruttero, R.; Biondi, S.; Ongini, E.; Gasco, A. (Nitrooxyacyloxy)methyl esters of aspirin as novel nitric oxide releasing aspirins. J. Med. Chem. 200952, 5058-5068.  doi

Chegaev, K.; Lazzarato, L.; Marcarino, P.; Di Stilo, A.; Fruttero, R.; Vanthuyne, N.; Roussel, C.; Gasco, A. Synthesis of some novel organic nitrates and comparative in vitro study of their vasodilator profile. J. Med. Chem. 200952, 4020-4025  doi

Guglielmo, S.; Bertinaria, M.; Rolando, B.; Crosetti, M.; Fruttero, R.; Yardley, V.; Croft, S. L.; Gasco, A. A new series of amodiaquine analogues modified in the basic side chain with in vitro antileishmanial and antiplasmodial activity. Eur. J. Med. Chem. 200944, 5071-5079  doi

Chegaev, K.; Cena, C.; Giorgis, M.; Rolando, B.; Tosco, P.; Bertinaria, M. Fruttero, R.; Carrupt, P.-A.; Gasco, A. Edaravone derivatives containing NO-donor functions. J. Med. Chem. 200952, 574-578  doi

Tosco, P.; Marini, E.; Rolando, B.; Lazzarato, L.; Cena, C.; Bertinaria, M.; Fruttero, R.; Reist, M.; Carrupt, P.-A.; Gasco, A. Structure-antioxidant activity relationships in a series of NO-donor phenols. ChemMedChem 20083, 1443-1448  doi

 

Campusnet Unito
Non cliccare qui!